(Q39808042)

14 September 2017

title

Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis (English)

1 reference

14 September 2017

Martin Hoyle

1

1 reference

14 September 2017

language of work or name

1 reference

1 January 2011

1 reference

14 September 2017

1 reference

14 September 2017

volume

29

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

1-15

1 reference

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

14 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11584230-000000000-00000

The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11584230-000000000-00000

Impact of generic drug entry on cost-effectiveness analysis

21 January 2018

1 reference

12 December 2020

Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.

1 reference

12 December 2020

Future drug prices and cost-effectiveness analyses.

1 reference

12 December 2020

Taking account of future technology in cost effectiveness analysis

1 reference

12 December 2020

The NICE cost-effectiveness threshold: what it is and what that means

1 reference

12 December 2020

Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts.

1 reference

12 December 2020

10.2165/11584230-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

14 September 2017

1028292192

0 references

1 reference